Sector
PharmaceuticalsOpen
₹5,280Prev. Close
₹5,300Turnover(Lac.)
₹11,369.26Day's High
₹5,289.5Day's Low
₹5,187.552 Week's High
₹5,933.552 Week's Low
₹5,075Book Value
₹1,218.48Face Value
₹2Mkt Cap (₹ Cr.)
62,293.37P/E
28.27EPS
187.45Divi. Yield
128 May 2026
12:00 AM
AGM
Announcement Date: 28 May, 2026
21 Jul 2026
12:00 AM
Board Meeting
Agenda : Audited Result
28 May 2026
12:00 AM
Dividend
Dividend Amount: 10
Record Date: 07 Aug, 2026
15 Jul 2026
12:00 AM
EGM
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 23.91 | 23.91 | 23.91 | 23.91 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 13,974.85 | 12,297.92 | 10,530.7 | 9,325.94 |
Net Worth | 13,998.76 | 12,321.83 | 10,554.61 | 9,349.85 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 8,829.81 | 7,219.68 | 6,677.08 | 5,300.26 |
yoy growth (%) | 22.3 | 8.12 | 25.97 | 16.53 |
Raw materials | -3,565.89 | -2,665.02 | -2,550.56 | -2,075.22 |
As % of sales | 40.38 | 36.91 | 38.19 | 39.15 |
Employee costs | -1,434.49 | -1,158.72 | -1,066.76 | -861.63 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,753.37 | 1,897.08 | 1,338.08 | 934.29 |
Depreciation | -218.98 | -198.93 | -186.84 | -107.65 |
Tax paid | -212.12 | -199.22 | -73.66 | -218.45 |
Working capital | 954.38 | 1,212.29 | 1,245.84 | 514.21 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.3 | 8.12 | 25.97 | 16.53 |
Op profit growth | -7.11 | 32.79 | 47.85 | 13.05 |
EBIT growth | -7.66 | 40.9 | 42.42 | 5.28 |
Net profit growth | -8.53 | 33.26 | 76.63 | -18.94 |
| Particulars (Rupees in Crores.) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|---|
Gross Sales | 14,712.27 | 12,964.52 | 12,667.58 | 11,599.26 | 10,634.19 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 14,712.27 | 12,964.52 | 12,667.58 | 11,599.26 | 10,634.19 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 583.35 | 493.74 | 310.84 | 216.08 | 162.65 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,929 | 145.47 | 4,63,179.62 | 1,115.14 | 0.83 | 5,641.31 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 9,165 | 81.21 | 2,43,301.95 | 891 | 0.33 | 2,974 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,965.5 | 91.97 | 1,88,622.52 | 492 | 0.68 | 4,073 | 222.76 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,167.8 | 31.86 | 1,16,114.43 | 339.6 | 0.09 | 2,723.5 | 237.3 |
Cipla Ltd CIPLA | 1,423 | 34.93 | 1,14,554.33 | 862.16 | 0.92 | 4,672.12 | 423.35 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman/ED & CEO
Basudeo N Singh
ED / MD / Promoter
SANDEEP SINGH
Executive Director
Mritunjay Kumar Singh
Executive Director
Madhurima Singh
Executive Director
SARVESH SINGH
Executive Director
Srinivas Singh
Independent Non Exe. Director
Narendra Aneja
Independent Non Exe. Director
Sujjain Talwar
Independent Non Exe. Director
Rajeev Kher
Independent Non Exe. Director
R L Shenoy
Independent Non Exe. Director
Neela Bhattacherjee
Independent Non Exe. Director
Diwakar Gupta
President / Company Secretary / Compliance Officer
Manish Narang
Alkem House SenapatiBapat Marg,
Lower Parel,
Maharashtra - 400013
Tel: 91-22-39829999
Website: http://www.alkemlabs.com
Email: investors@alkem.com ; contact@alkem.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: https://in.mpms.mufg.com
Email: rnt.helpdesk@in.mpms.mufg.com
Summary
Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The Company is engaged in the development, manufacture and sale of pharmac...
Read More
Reports by Alkem Laboratories Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
